Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclatasvir and Sofosbuvir With or Without Ribavirin in HCV Genotype 3
NCT02551861Phase 2Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of daclatasvir in hepatitis C (HCV) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Sustained Virologic Response at Week 12. Planned start Dec 2015; status: withdrawn.
02
Drugs
daclatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02551861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02551861.